Versant Venture Capital VI, L.P. - 04 Apr 2024 Form 3 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
10%+ Owner
Signature
Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer
Issuer symbol
CTNM
Transactions as of
04 Apr 2024
Net transactions value
$0
Form type
3
Filing time
04 Apr 2024, 21:22:01 UTC
Previous filing
25 Mar 2024
Next filing
11 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTNM Class A Common Stock 375,535 04 Apr 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTNM Series A Preferred Stock 04 Apr 2024 Class A Common Stock 1,775,421 See Footnote F2, F3
holding CTNM Series B Preferred Stock 04 Apr 2024 Class A Common Stock 418,641 See Footnote F2, F3
holding CTNM Series C Preferred Stock 04 Apr 2024 Class A Common Stock 132,499 See Footnote F2, F3
holding CTNM Series A Preferred Stock 04 Apr 2024 Class A Common Stock 11,183 See Footnote F2, F4
holding CTNM Series B Preferred Stock 04 Apr 2024 Class A Common Stock 2,637 See Footnote F2, F4
holding CTNM Series C Preferred Stock 04 Apr 2024 Class A Common Stock 834 See Footnote F2, F4
holding CTNM Series B Preferred Stock 04 Apr 2024 Class A Common Stock 525,472 See Footnote F2, F5
holding CTNM Series C Preferred Stock 04 Apr 2024 Class A Common Stock 333,334 See Footnote F2, F5
holding CTNM Series A-1 Preferred Stock 04 Apr 2024 Class A Common Stock 1,423,119 Direct F1, F2
holding CTNM Series B Preferred Stock 04 Apr 2024 Class A Common Stock 317,988 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held directly by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.
F2 Upon the closing of the Issuer's initial public offering (the "IPO"), each of the outstanding shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (collectively, the "Preferred Stock"), will automatically convert into shares of the Issuer's Class A common stock, on a one-for-one basis for no additional consideration, in accordance with the provisions of the Issuer's amended and restated certificate of incorporation, with the exception of certain shares of the Preferred Stock, which the Reporting Persons herein may elect, prior to the closing of the IPO, to convert into shares of the Issuer's Class B common stock. The Preferred Stock has no expiration Date.
F3 The shares are held directly by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV GP") is the general partner of VVC IV and disclaims beneficial ownership of the shares held by VVC IV, except to the extent of its pecuniary interest therein.
F4 The shares are held directly by Versant Side Fund IV, L.P. ("VSF IV"). VV IV GP is the general partner of VSF IV and disclaims beneficial ownership of the shares held by VSF IV, except to the extent of its pecuniary interest therein.
F5 The shares are held directly by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.